Enablex

Enablex is a brand name of darifenacin, approved by the FDA in the following formulation(s):

ENABLEX (darifenacin hydrobromide - tablet, extended release; oral)

• 
  Manufacturer: WARNER CHILCOTT LLC
  
  Approval date: December 22, 2004
  
  Strength(s): EQ 15MG BASE ^[RLD], EQ 7.5MG BASE
  

Has a generic version of Enablex been approved?

No. There is currently no therapeutically equivalent version of Enablex available.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Enablex. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

• 
  Pyrrolidine derivatives
  Patent 5,096,890
  Issued: March 17, 1992
  Inventor(s): Cross; Peter E. & MacKenzie; Alexander R.
  Assignee(s): Pfizer Inc.
  Compounds of the formula ##STR1## wherein R, Y and R.sup.1 are as defined in the specification. These compounds are muscarinic receptor antagonists which are selective for smooth muscle muscarinic sites over cardiac muscarinic sites, and are useful in the treatment of diseases associated with altered motility on tone of smooth muscle, including irritable bowel syndrome, diverticular disease, urinary incontinence, oesophageal achalasia and chronic obstructive airways disease.
  
  Patent expiration dates:
  
  
  • March 13, 2015
    
    ✓ 
    Patent use: TREATING A DISEASE OF ALTERED MOTILITY OR TONE OF SMOOTH MUSCLE BY ADMINISTERING A MUSCARINIC RECEPTOR ANTAGONIZING AMOUNT OF DARIFENACIN
    ✓ 
    Drug substance
    ✓ 
    Drug product
  
  



• 
  Pharmaceutical formulations containing darifenacin
  Patent 6,106,864
  Issued: August 22, 2000
  Inventor(s): Dolan; Thomas Francis & Humphrey; Michael John & Nichols; Donald John
  Assignee(s): Pfizer Inc.
  There is provided a pharmaceutical dosage form adapted for administration to the gastrointestinal tract of a patient, comprising darifenacin, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable adjuvant, diluent or carrier, characterized in that the dosage form is adapted to deliver at least 10% by weight of the darifenacin, or the pharmaceutically acceptable salt thereof, to the lower gastrointestinal tract of the patient. The formulation minimizes unwanted side-effects and increases the bioavailability of darifenacin.
  
  Patent expiration dates:
  
  
  • August 21, 2016
    
    ✓ 
    Patent use: TREATING URINARY INCONTINENCE BY ADMINISTERING AN EXTENDED-RELEASE FORM OF DARIFENACIN
    ✓ 
    Drug product
  
  

See also...

• Enablex Consumer Information (Drugs.com)
• Enablex Extended-Release Tablets Consumer Information (Wolters Kluwer)
• Enablex Consumer Information (Cerner Multum)
• Enablex Advanced Consumer Information (Micromedex)
• Enablex AHFS DI Monographs (ASHP)
• Darifenacin Extended-Release Tablets Consumer Information (Wolters Kluwer)
• Darifenacin Consumer Information (Cerner Multum)
• Darifenacin Advanced Consumer Information (Micromedex)
• Darifenacin Hydrobromide AHFS DI Monographs (ASHP)